The 340B Drug Discount Program: Hospitals Generate Profits By Expanding To Reach More Affluent Communities

被引:51
|
作者
Conti, Rena M. [1 ,2 ]
Bach, Peter B. [3 ]
机构
[1] Univ Chicago, Dept Pediat, Chicago, IL 60637 USA
[2] Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA
[3] Mem Sloan Kettering Canc Ctr, Ctr Hlth Policy & Outcomes, New York, NY 10021 USA
关键词
PHYSICIAN RELATIONS; COST; INTEGRATION;
D O I
10.1377/hlthaff.2014.0540
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
The federal 340B program gives participating hospitals and other medical providers deep discounts on outpatient drugs. Named for a section of the Veterans Health Care Act of 1992, the program's original intent was to help low-income and uninsured patients. But the program has come under scrutiny by critics who contend that some hospitals exploit the drug discounts to generate profits instead of either investing in programs for the poor or passing the discounts along to patients and insurers. We examined whether the program is expanding in ways that could maximize hospitals' ability to generate profits from the 340B drug discounts. We matched data for 960 hospitals and 3,964 affiliated clinics registered with the 340B program in 2012 with the socioeconomic characteristics of their communities from the US Census Bureau's American Community Survey. We found that hospital-affiliated clinics that registered for the 340B program in 2004 or later served communities that were wealthier and had higher rates of health insurance compared to communities served by hospitals and clinics that registered for the program before 2004. Our findings support the criticism that the 340B program is being converted from one that serves vulnerable patient populations to one that enriches hospitals and their affiliated clinics.
引用
收藏
页码:1786 / 1792
页数:7
相关论文
共 50 条
  • [41] The Impact of Patient Assistance Programs and the 340B Drug Pricing Program on Medication Cost
    Castellon, Yelba M.
    Bazargan-Hejazi, Shahrzad
    Masatsugu, Miles
    Contreras, Roberto
    AMERICAN JOURNAL OF MANAGED CARE, 2014, 20 (02): : 146 - 150
  • [42] Access To Oncology Services In Rural Areas: Influence Of The 340B Drug Pricing Program
    Owsley, Kelsey M.
    Bradley, Cathy J.
    HEALTH AFFAIRS, 2023, 42 (06) : 785 - 794
  • [43] Impact of the 340B Drug Pricing Program on Cancer Care Site and Spending in Medicare
    Jung, Jeah
    Xu, Wendy Y.
    Kalidindi, Yamini
    HEALTH SERVICES RESEARCH, 2018, 53 (05) : 3528 - 3548
  • [45] Policy Statement on the 340B Drug Pricing Program by the American Society of Clinical Oncology
    Tomkins, Julia E.
    JOURNAL OF ONCOLOGY PRACTICE, 2014, 10 (04) : 259 - 263
  • [46] Reforming the 340B Drug Pricing Program: Tradeoffs Between Hospital and Manufacturer Revenues
    Coukell, Allan J.
    Dickson, Sean
    JAMA INTERNAL MEDICINE, 2018, 178 (08) : 1127 - +
  • [47] The 340B Drug Pricing Program and oral specialty drugs for advanced prostate cancer.
    Faraj, Kassem S.
    Kaufman, Samuel
    Herrel, Lindsey A.
    Oerline, Mary
    Caram, Megan Veresh
    Shahinian, Vahakn B.
    Hollenbeck, Brent K.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 26 - 26
  • [48] The 340b Program, Contract Pharmacies, Hospitals, and Patients An Evolving Relationship Impacting Health Care Delivery
    Ruley, Morgan
    Belcher, Morgan
    Sayre, Hannah
    Coustasse, Alberto
    HEALTH CARE MANAGER, 2019, 38 (04) : 311 - 321
  • [49] Addressing financial toxicity in cancer treatment-An opportunity for the 340B drug pricing program
    Faraj, Kassem S.
    Caram, Megan E. V.
    Shahinian, Vahakn B.
    Hollenbeck, Brent K.
    CANCER, 2024, 130 (18) : 3077 - 3081
  • [50] Economic Evaluation of Changes in Reimbursement for Medications Purchased Through the 340B Drug Pricing Program
    Endriukaitis, Lauren A.
    Hayes, Genevieve L.
    Mills, Jason
    HOSPITAL PHARMACY, 2021, 56 (04) : 235 - 240